Immunoassays – Webinars and Online Events

In bioprocessing, it is critical that host cell proteins (HCPs) can be identified, detected and removed so that the efficacy of the drug is not impacted, and custom process-specific HCP ELISA are typically the preferred method for measuring these contaminants.

In this webinar, our expert speaker, Professor Lei Liu, Assistant Professor of Neurology from Harvard Medical School will discuss strategies in developing an ultrasensitive immunoassay* to measure oligomeric amyloid β in human plasma precisely.

Traditional Western blot workflows are notoriously labor-intensive and limited in reproducibility, quantification, sensitivity and multiplexing capabilities.

Join Dr Natalia Sannikova and Tomas Skrinskas from Ascension Sciences, as they explore the therapeutic use of cannabinoids as novel medicines and the opportunities of nanotechnology in formulating cannabinoid nanoparticles.

The manufacturing process for cell and gene therapies is complex and can contain process-related impurities from multiple organisms. A commercial host cell protein (HCP)-ELISA kit is often not available for the cell line or is not suitable for the specific process due to a low HCP coverage. Development of a process-specific ELISA can be unfeasible as the product often requires a short development time.